<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01082679</url>
  </required_header>
  <id_info>
    <org_study_id>H-2008-0242</org_study_id>
    <nct_id>NCT01082679</nct_id>
  </id_info>
  <brief_title>Treatment for Opioid Dependent Offenders</brief_title>
  <official_title>Treatment for Opioid Dependent Offenders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Wisconsin, Milwaukee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is examining the feasibility of a primary care and a specialist treatment
      (methadone clinic) model of treatment for 15 offenders who are part of two community
      supervision programs: Drug Court and the Treatment Alternative Program (TAP) in Dane County.
      The questions addressed by future larger studies based upon the current pilot-feasibility
      study will center around whether access to primary health care as opposed to more traditional
      methadone treatment services will improve the health and criminal justice outcomes for
      participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retention rate of participants in the study</measure>
    <time_frame>12 months</time_frame>
    <description>This study is focused on Dane County Drug Treatment Court and Treatment Alternative Program participants.
The study will determine feasibility of monitoring participants in primary care as opposed to the usual standard of specialty care.
Feasibility of monitoring participants will be studied in terms of retention rate of participants in the study</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Opioid Dependence</condition>
  <arm_group>
    <arm_group_label>methadone via specialty care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Suboxone via specialty care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Suboxone via primary care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone</intervention_name>
    <description>daily for 12 months</description>
    <arm_group_label>methadone via specialty care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buprenorphine (Suboxone)</intervention_name>
    <description>daily for 12 months</description>
    <arm_group_label>Suboxone via primary care</arm_group_label>
    <arm_group_label>Suboxone via specialty care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of opioid dependence

          -  opioid positive urine drug screen

          -  participation in local Drug Treatment Court or Treatment Alternative Program

          -  women of childbearing potential who have a negative screening urine pregnancy test and
             are willing to use appropriate birth control methods during the duration of the study

        Exclusion Criteria:

          -  current alcohol or sedative dependence

          -  pregnancy

          -  women who are currently breast-feeding

          -  complex psychiatric co-morbidity (e.g. suicidality, psychosis)

          -  complex medical co-morbidity (e.g. major cardiovascular, renal, or
             gastrointestinal/hepatic disease)

          -  current pharmacotherapy with an agent which is contraindicated in combination with
             Suboxone or methadone according to drug labeling

          -  paralytic ileus, coronary artery disease or heart arrhythmia, recent head injury,
             obstructive sleep apnea, severe asthma or COPD, end-stage renal disease, or severe
             morbid obesity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randy Brown, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin - Madison, Department of Family Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin - Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Brown R, Gassman M, Hetzel S, Berger L. Community-based treatment for opioid dependent offenders: a pilot study. Am J Addict. 2013 Sep-Oct;22(5):500-2. doi: 10.1111/j.1521-0391.2013.12049.x. Epub 2013 Apr 3.</citation>
    <PMID>23952897</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 5, 2010</study_first_submitted>
  <study_first_submitted_qc>March 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2010</study_first_posted>
  <last_update_submitted>May 15, 2019</last_update_submitted>
  <last_update_submitted_qc>May 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>opioid dependent</keyword>
  <keyword>methadone</keyword>
  <keyword>Suboxone</keyword>
  <keyword>buprenorphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

